August 6, 2026 Copenhagen, Denmark — Interim Report for the Six Months Ended June 30, 2026

Highlights

Genmab announced positive Phase 3 results for epcoritamab plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma. The combination showed a statistically significant improvement in progression-free survival, reinforcing epcoritamab's positioning in an increasingly competitive CD3xCD20 bispecific antibody landscape that also includes Roche's glofitamab and mosunetuzumab.

Genmab revenue increased 25% from the first six months of 2025 to $2,051 million.

Genmab updated its 2026 financial guidance.

“The second quarter of 2026 delivered clinical progress for our late-stage portfolio. Epcoritamab continued to demonstrate its potential as a core therapy across the spectrum of B-cell malignancies, with strong data across multiple treatment settings and patient populations. At the same time, new data further support the development of Rina-S ® (rinatabart sesutecan) in combination in advanced ovarian cancer. Together, these results reflect our continued commitment to delivering meaningful advances for patients,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

Financial Performance for the First Half of 2026

Revenue was $2,051 million for the first six months of 2026, compared with $1,640 million for the first six months of 2025. The increase of $411 million, or 25%, was primarily driven by higher DARZALEX ® and Kesimpta ® royalties and higher EPKINLY ® net product sales. DARZALEX, marketed by J&J, is a CD38-directed antibody used across multiple myeloma treatment lines, while Kesimpta, marketed by Novartis, is a subcutaneous anti-CD20 therapy for relapsing multiple sclerosis.

Royalty revenue was $1,708 million in the first six months of 2026, compared with $1,378 million in the first six months of 2025, an increase of $330 million, or 24%. The increase was driven by higher net sales of DARZALEX and Kesimpta.

Net sales of DARZALEX by J&J were $8,171 million in the first six months of 2026, compared with $6,776 million in the first six months of 2025, an increase of $1,395 million, or 21%.

Global net sales of EPKINLY/TEPKINLY ® were $312 million in the first six months of 2026, compared with $211 million in the first six months of 2025, an increase of $101 million, or 48%. EPKINLY, co-developed with AbbVie, is currently approved in certain relapsed/refractory B-cell lymphoma indications, and the positive Phase 3 data in combination with lenalidomide could support potential label expansion into earlier treatment settings.

Cost of product sales was $149 million for the first six months of 2026, compared with $99 million for the first six months of 2025. The increase of $50 million, or 51%, was primarily driven by the profit-sharing amounts payable to AbbVie related to EPKINLY sales.

Adjusted operating expenses, excluding acquisition and integration-related charges, were $1,270 million for the first six months of 2026, compared with $993 million for the first six months of 2025. The increase of $277 million, or 28%, was primarily driven by investment in the company's product pipeline, including the advancement of Rina-S and petosemtamab, and global commercialization capabilities in preparation for their anticipated launches. Rina-S, an antibody-drug conjugate targeting folate receptor alpha, was acquired through Genmab's completed acquisition of ProfoundBio and is being developed for advanced ovarian cancer. Petosemtamab is a bispecific antibody targeting EGFR and LGR5 in development for epithelial tumors.

Acquisition and integration-related charges related to the integration of Merus were $77 million in the first six months of 2026.

Amortization of acquired intangible assets was $24 million for the first six months of 2026, compared with $6 million for the first six months of 2025. The increase of $18 million was primarily driven by amortization of the Merus technology platform.

Operating profit was $555 million in the first six months of 2026, compared with $548 million in the first six months of 2025. Adjusted operating profit, which excludes acquisition and integration-related charges and amortization of acquired intangible assets, was $656 million in the first six months of 2026, compared with $554 million in the first six months of 2025.

Outlook

Genmab is updating its 2026 revenue, adjusted operating expenses and adjusted operating profit guidance. The improved outlook is driven by higher total royalty revenues from DARZALEX and net sales of EPKINLY.

2026 Full-Year Outlook

1. Net product sales/collaboration revenue consists of EPKINLY net product sales in the U.S. and Japan, and Tivdak ® ex-U.S. net product sales plus Genmab's share of U.S. gross profits.
2. Adjusted operating expenses and operating profit exclude 2026 charges related to: 1) acquisition and integration-related charges of $90 million and 2) amortization of intangible assets acquired through acquisitions of $47 million.
3. Adjusted operating expenses and operating profit exclude 2026 charges related to: 1) acquisition and integration-related charges of $65 million and 2) amortization of intangible assets acquired through acquisitions of $45 million.

Non-IFRS Financial Measures

Genmab's adjusted operating expenses and adjusted operating profit exclude acquisition and integration-related charges and amortization of acquired intangible assets. The company said these charges were recognized in prior periods and will likely recur in future periods.

The company said these items are excluded because they do not relate to the ordinary course of its business and do not reflect underlying business performance. Genmab said non-IFRS information is intended to portray baseline performance, supplement management's, analysts' and investors' understanding of underlying financial performance, and facilitate comparisons among current, past and future periods.

The company said non-IFRS information should not be considered in isolation or as a substitute for IFRS financial measures, and may not be comparable with similarly titled measures used by other companies because of differences in methodology and adjusted items.

Conference Call

Genmab will hold a conference call to discuss the results for the first six months of 2026 on Thursday, August 6, at 6:00 pm CEST, 5:00 pm BST, or 12:00 pm EDT.

Registered participants can use this link to join: . Registered participants will receive an email with a link to access dial-in information and a unique personal PIN.

A live and archived webcast of the call and relevant slides will be available at www.genmab.com/investor-relations .

Contact

Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065
E: mmp@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558
E: acn@genmab.com

Forward-Looking Statements

The interim report contains forward-looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan,” and similar expressions identify forward-looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by these statements.

Factors that could cause actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of Genmab's products, the company's inability to manage growth, the competitive environment in its business area and markets, the inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of patents and proprietary rights, relationships with affiliated entities, and changes and developments in technology that may render products or technologies obsolete.

For further discussion of these risks, see the risk management sections in Genmab's most recent financial reports, available at www.genmab.com, and the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission, available at www.sec.gov .

Genmab does not undertake any obligation to update or revise forward-looking statements in the interim report or to confirm such statements to reflect subsequent events or circumstances after the date made, or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab ® ; the Y-shaped Genmab logo ® ; Genmab in combination with the Y-shaped Genmab logo ® ; HuMax ® ; DuoBody ® ; HexaBody ® ; DuoHexaBody ® ; HexElect ® ; KYSO ® , RAINFOL™, ProfoundBio™ and Rina-S ® are trademarks of ProfoundBio, U.S., Co. and Genmab (Suzhou) Co., Ltd. Tivdak ® is a trademark of Seagen Inc.; EPCORE ® , EPKINLY ® , TEPKINLY ® and their designs are trademarks of AbbVie Biotechnology Ltd.; Biclonics ® and BIZENGRI ® are registered trademarks of Merus N.V. Kesimpta ® and Sensoready ® are trademarks of Novartis AG or its affiliates; DARZALEX ® , DARZALEX FASPRO ® , RYBREVANT ® , RYBREVANT FASPRO™, TECVAYLI ® and TALVEY ® are trademarks of Johnson & Johnson; TEPEZZA ® is a trademark of Horizon Therapeutics Ireland DAC.

Download the full Interim Report for the First Half of 2026 on attachment or at www.genmab.com/investor-relations

CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122

Genmab A/S
Carl Jacobsens Vej 30
2500 Valby
Denmark

Attachment: 060826_CA34_Genmab Interim Report H1 2026